title: [Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?]
abstract: Erlotinib can be prescribed in the treatment of locally advanced or metastatic non-small lung cancer cell (NSCLC) after failure of at least one prior chemotherapy regimen on the basis of the BR-21 study. Several publications have recently questioned these results. The metabolic imaging of solid tumours by positron emission tomography is a research field that could help customize the treatment of NSCLC and so complement the treatment approaches allowed by genetic analyses. This strategy is part of an innovative "early metabolic look" approach. The primary objective of this study is to determine if metabolic progression observed between the 7th and 14th day after initiation of treatment with erlotinib by 3'-Deoxy-3'-[18F]-Fluorothymidine PET in patients with EGFR naive NSCLC is predictive for morphological progression after 6 to 8 weeks of treatment. A health economic analysis will be conducted. This study is particularly innovative because it begins the exploration of the era of metabolic evaluation of therapeutic response in NSCLC.
authors.affiliation: Département de pneumologie, allergologie et oncologie, LUNAM université, centre hospitalier universitaire, 4, rue Larrey, 49933 Angers cedex 9, France. Electronic address: johureaux@chu-angers.fr.
authors.forename: J
authors.initials: J
authors.lastname: Hureaux
authors.affiliation: Service de médecine nucléaire, LUNAM université, centre hospitalier universitaire, 4, rue Larrey, 49933 Angers cedex 9, France.
authors.forename: O
authors.initials: O
authors.lastname: Couturier
authors.affiliation: Service de médecine nucléaire, LUNAM université, centre hospitalier universitaire, 4, rue Larrey, 49933 Angers cedex 9, France.
authors.forename: F
authors.initials: F
authors.lastname: Lacœuille
authors.affiliation: Service de médecine nucléaire, LUNAM université, centre hospitalier universitaire, 4, rue Larrey, 49933 Angers cedex 9, France.
authors.forename: F
authors.initials: F
authors.lastname: Bouchet
authors.affiliation: Service de pneumologie, centre interhospitalier de Créteil, 94000 Créteil, France.
authors.forename: C
authors.initials: C
authors.lastname: Chouaïd
authors.affiliation: DRCI - cellule de méthodologie et de biostatistiques, centre hospitalier universitaire, 4, rue Larrey, 49933 Angers cedex 9, France.
authors.forename: P
authors.initials: P
authors.lastname: Saulnier
authors.affiliation: Département de pneumologie, allergologie et oncologie, LUNAM université, centre hospitalier universitaire, 4, rue Larrey, 49933 Angers cedex 9, France.
authors.forename: T
authors.initials: T
authors.lastname: Urban
mesh_terms: D054316:Biomarkers, Pharmacological / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016903:Drug Monitoring / Q000379:methods*; D000069347:Erlotinib Hydrochloride / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D049268:Positron-Emission Tomography; D057285:Precision Medicine / Q000379:methods; D011237:Predictive Value of Tests; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D054316:Biomarkers, Pharmacological; D000069347:Erlotinib Hydrochloride
keywords: 3′-Désoxy-3′-[(18)F]-Fluorothymidine; Alovudine; Cancer bronchique non à petites cellules; Erlotinib; Non-small cell lung cancer; Positron emission tomography; Tomographie par émission de positons